ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Results From the TAPUR Study: Pertuzumab + Trastuzumab for Biliary Tract Cancer With ERBB2/3 Amplification, Overexpression, or Mutation
By
ASCO GI 2023 Conference Coverage
FEATURING
Timothy Cannon
By
ASCO GI 2023 Conference Coverage
FEATURING
Timothy Cannon
159 views
February 7, 2023
Login to view comments.
Click here to Login
Videos